Lupin finalized the acquisition of two brands from Sanofi: Aarane in Germany and Nalcrom in Canada and the Netherlands, along with their associated trademark rights.
Fabrice Egros, Lupin’s President of Corporate Development, stated that the acquisition would bolster the company’s global presence in treating various respiratory diseases and conditions, while also enhancing its portfolio in gastrointestinal care.
As reported by businessline, in December, the Mumbai based pharmaceutical company announced that its Swiss subsidiary, Lupin Atlantis Holdings SA, had entered into an asset purchase agreement with the French multinational Sanofi to acquire a collection of established products in Europe and Canada.
